贝达药业
(300558)
| 流通市值：199.63亿 | | | 总市值：200.27亿 |
| 流通股本：4.19亿 | | | 总股本：4.21亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,717,342,723.91 | 1,731,412,742.27 | 917,554,506.92 | 2,891,950,112.03 |
| 营业收入 | 2,717,342,723.91 | 1,731,412,742.27 | 917,554,506.92 | 2,891,950,112.03 |
| 二、营业总成本 | 2,301,749,460.62 | 1,494,357,686.84 | 730,520,724.15 | 2,460,400,758.66 |
| 营业成本 | 534,313,542.97 | 325,829,280.36 | 171,801,799.66 | 538,519,341.59 |
| 税金及附加 | 31,561,300.02 | 20,088,952.57 | 11,539,267.84 | 21,270,693.65 |
| 销售费用 | 929,022,001.15 | 593,574,184.3 | 280,153,932.19 | 1,093,819,859.43 |
| 管理费用 | 372,296,453.39 | 260,676,979.92 | 132,893,502.91 | 268,858,962.29 |
| 研发费用 | 372,969,710.8 | 254,657,824.51 | 113,293,329.82 | 501,901,633.96 |
| 财务费用 | 61,586,452.29 | 39,530,465.18 | 20,838,891.73 | 36,030,267.74 |
| 其中:利息费用 | 57,513,928.75 | 38,893,556.28 | 21,648,799.45 | 45,490,039.66 |
| 其中:利息收入 | 3,925,199.77 | 3,062,516.11 | 1,603,972.57 | 6,782,043.94 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -48,026,625.59 | -76,016,377.9 | -76,599,780.35 | -26,305,321.32 |
| 加:投资收益 | -9,911,270.35 | -6,504,780.23 | -3,160,629.58 | -14,663,608.75 |
| 资产处置收益 | 72,940.02 | 72,940.02 | 65,136.6 | -588,954.91 |
| 资产减值损失(新) | - | - | - | -27,460,186.2 |
| 信用减值损失(新) | 689,655.85 | 2,647,368.81 | 533,384.23 | 6,303,473.83 |
| 其他收益 | 36,073,974.44 | 30,893,563.66 | 15,195,343.44 | 31,036,928.55 |
| 四、营业利润 | 394,491,937.66 | 188,147,769.79 | 123,067,237.11 | 399,871,684.57 |
| 加:营业外收入 | 1,008,120.46 | 1,009,542.57 | 409,148.58 | 1,255,593.56 |
| 减:营业外支出 | 3,926,011.16 | 1,341,243.13 | 323,717.14 | 6,969,176.49 |
| 五、利润总额 | 391,574,046.96 | 187,816,069.23 | 123,152,668.55 | 394,158,101.64 |
| 减:所得税费用 | 88,567,954.95 | 57,108,668.13 | 27,689,152.07 | 7,178,699.06 |
| 六、净利润 | 303,006,092.01 | 130,707,401.1 | 95,463,516.48 | 386,979,402.58 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 303,006,092.01 | 130,707,401.1 | 95,463,516.48 | 386,979,402.58 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 316,932,355.32 | 139,897,221.85 | 100,089,181.47 | 402,569,335.69 |
| 少数股东损益 | -13,926,263.31 | -9,189,820.75 | -4,625,664.99 | -15,589,933.11 |
| 扣除非经常损益后的净利润 | 337,227,246.42 | 190,623,726.76 | 164,430,292.77 | 409,834,141.43 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.76 | 0.33 | 0.24 | 0.96 |
| (二)稀释每股收益 | 0.75 | 0.33 | 0.24 | 0.96 |
| 八、其他综合收益 | 43,432,024.6 | -148,106,979.63 | -137,880,994.15 | 56,915,948.89 |
| 归属于母公司股东的其他综合收益 | 43,432,024.6 | -148,106,979.63 | -137,880,994.15 | 56,915,948.89 |
| 九、综合收益总额 | 346,438,116.61 | -17,399,578.53 | -42,417,477.67 | 443,895,351.47 |
| 归属于母公司股东的综合收益总额 | 360,364,379.92 | -8,209,757.78 | -37,791,812.68 | 459,485,284.58 |
| 归属于少数股东的综合收益总额 | -13,926,263.31 | -9,189,820.75 | -4,625,664.99 | -15,589,933.11 |
| 公告日期 | 2025-10-28 | 2025-08-20 | 2025-04-25 | 2025-04-18 |
| 审计意见(境内) | | | | 标准无保留意见 |